For Healthcare Professionals

Efficacy and Safety Assessment of T4030 Eye Drops Versus Ganfort® UD in Ocular Hypertensive or Glaucomatous Patients.

clipboard-pencil

About the study

To demonstrate the non-inferiority of T4030 unpreserved eye drops compared to Ganfort® UD in terms of efficacy.
user-3

Who can take part

You may be eligible to participate in the study if you meet the following criteria:

INCLUSION CRITERIA

  1. Informed consent signed and dated*
  2. Patient aged ≥18 years old
  3. Both eyes with a central corneal thickness assessment ≥500 µm and ≤600 μm a
  4. Both eyes with diagnosed ocular hypertension or open angle glaucoma

EXCLUSION CRITERIA

  1. History of narrow angle and/or angle closure glaucoma
  2. Advanced stage of glaucoma
pin location

Study Locations

Enter your ZIP code/Postal code/PIN code to locate study sites near you:

How to Apply


Contact the study center to learn if this study is a good match for you.
Phone iconCall 0635156436Email iconEmail Study Center

Study’s details


Contition

Ocular Hypertension Glaucoma

Age

18+

Phase

Phase 3

Participants needed

500

Est. Completion Date

Nov 2022

Treatment type

Interventional


Sponsor

Laboratoires Thea

ClinicalTrials.gov identifier

NCT04898387

Study number

LT4030-301

Understanding Clinical Trials


Get answers to your questions about clinical trials.What is a clinical research?What does taking part in clinical trials involve?What should I ask the trial doctor?
Vector

Interested?

Sign up to save your favorites, 
receive newsletters, resources, and alerts 
about clinical trials related to your conditions of interest.